Evidence map›Paper›PMID 31220480›Full record

ArticleThe Journal of hospital infection2019

Two-year analysis of Clostridium difficile ribotypes associated with increased severity.

R Herbert, J Hatcher, E Jauneikaite, M Gharbi, S d'Arc, N Obaray, T Rickards, M Rebec, O Blandy, R Hope and 4 more

Abstract read
In one paragraph

Article in The Journal of hospital infection, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. An Investigation into the Prevalence ofAntibiotics (Basel, Switzerland) · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Characterization of Food ChainMicroorganisms · 2023
    Article
  6. Microorganisms · 2022
    Article
  7. Detection and Genomic Characterisation ofPathogens (Basel, Switzerland) · 2022
    Article
  8. Biological characteristics associated with virulence inEmerging microbes & infections · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

R HerbertImperial College Healthcare NHS Trust, London, UK.
J HatcherImperial College Healthcare NHS Trust, London, UK.
E JauneikaiteNIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.
M GharbiNIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.
S d'ArcImperial College Healthcare NHS Trust, London, UK.
N ObarayImperial College Healthcare NHS Trust, London, UK; NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.
T RickardsImperial College Healthcare NHS Trust, London, UK.
M RebecImperial College Healthcare NHS Trust, London, UK.
O BlandyNIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.
R HopeNIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK; National Infection Service, Public Health England, London, UK.
A ThomasNIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.
K BamfordImperial College Healthcare NHS Trust, London, UK.
A JepsonImperial College Healthcare NHS Trust, London, UK.
S SriskandanImperial College Healthcare NHS Trust, London, UK; NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK. Electronic address: s.sriskandan@imperial.ac.uk.

Funding

Medical Research Council G0800777Medical Research Council MR/R015600/1
6 · The paper itself

Abstract

backgroundCertain Clostridium difficile ribotypes have been associated with complex disease phenotypes including recurrence and increased severity, especially the well-described hypervirulent RT027. This study aimed to determine the pattern of ribotypes causing infection and the association, if any, with severity.

methodsAll faecal samples submitted to a large diagnostic laboratory for C. difficile testing between 2011 and 2013 were subject to routine testing and culture. All C. difficile isolates were ribotyped, and associated clinical and demographic patient data were retrieved and linked to ribotyping data.

resultsIn total, 86 distinct ribotypes were identified from 705 isolates of C. difficile. RT002 and RT015 were the most prevalent (22.5%, N=159). Only five isolates (0.7%) were hypervirulent RT027. Ninety of 450 (20%) patients with clinical information available died within 30 days of C. difficile isolation. RT220, one of the 10 most common ribotypes, was associated with elevated median C-reactive protein and significantly increased 30-day all-cause mortality compared with RT002 and RT015, and with all other ribotypes found in the study.

conclusionsA wide range of C. difficile ribotypes were responsible for C. difficile infection presentations. Although C. difficile-associated mortality has reduced in recent years, expansion of lineages associated with increased severity could herald increases in future mortality. Enhanced surveillance for emerging lineages such as RT220 that are associated with more severe disease is required, with genomic approaches to dissect pathogenicity.

Indexed as

RibotypingAdolescentAdultAgedAged, 80 and overChildChild, PreschoolClostridioides difficileClostridium InfectionsFecesFemaleGenetic VariationHumansMaleMiddle AgedSeverity of Illness IndexClostridium difficileC-reactive proteinRibotypeSevere infectiontcdAtcdB

Identifiers

PMID31220480
PMCPMC6926500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.